Glenn J. Hanna
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Glenn J. Hanna sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Glenn J. Hanna: 7 sponsored US clinical trials, 5 recruiting.
Glenn J. Hanna sponsors 7 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Adenoid Cystic Carcinoma, with 3 trials.
Upper-quartile sponsor footprint
Glenn J. Hanna sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Toripalimab With Chemotherapy for Sinus Cancer
NCT06940180
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
NCT06805617
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
NCT06623110
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
NCT06239220
CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
NCT05774899
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NCT05010629
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
NCT05057247
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
Therapeutic Areas
What is open in the Glenn J. Hanna pipeline
5 recruiting of 7 indexed (71% open); 1 completed (14%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Adenoid Cystic Carcinoma (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Glenn J. Hanna: open-pipeline peers nationwide
Peers matched on 7 registered trials and 71% open enrollment, not the therapeutic-area sidebar.
Glenn J. Hanna sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 71% open enrollment (± trial volume)
- Anna Stanhewicz, PhD · 71% recruiting · 14 trials
- Senthil Sadhasivam · 71% recruiting · 7 trials
- CorEvitas · 69% recruiting · 13 trials
- Revolution Medicines · 69% recruiting · 16 trials
Related
What to do with this Glenn J. Hanna page
7 registered trials is a research-attention snapshot, not an endorsement of Glenn J. Hanna or any single study.
- 5 of Glenn J. Hanna's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Adenoid Cystic Carcinoma is the condition Glenn J. Hanna studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Adenoid Cystic Carcinoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Glenn J. Hanna pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.